The New Xpert MTB/RIF Ultra: Improving Detection of *Mycobacterium tuberculosis* and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing

Soumitesh Chakravorty,a Ann Marie Simmons,b Mazhgan Rowneki,a Heta Parmar,a Yuan Cao,a Jamie Ryan,a Padmapriya P. Banada,b Srinidhi Deshpande,a Shubhada Shenai,a Alexander Gall,c Jennifer Glass,c Barry Krieswirth,d Samuel G. Schumacher,a Pamela Nabetab,e Nestani Tukvadze,f Camilla Rodrigues,g Alena Skrahinan,h Elisa Tagliani,i Daniela M. Cirillo,i Amy Davidow,j Claudia M. Denkinger,a David Persing,b Robert Kwiatkowski,b Martin Jones,b David Allandb

Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USAa; Cepheid Inc., Sunnyvale, California, USAb; Cepheid Inc., Bothell, Washington, USAc; Public Health Research Institute, Rutgers, New Jersey Medical School, Newark, New Jersey, USAd; Foundation for Innovative New Diagnostics, Geneva, Switzerlande; National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgiaf; P. D. Hinduja National Hospital and Medical Research Centre, Mumbai, Indiag; National Reference Laboratory, Republican Scientific and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarusb; Emerging Bacterial Pathogens Unit, San Raffaele Scientific Institute, Milan, Italyi; Department of Preventive Medicine and Community Health, Rutgers, New Jersey Medical School, Newark, New Jersey, USAj

**ABSTRACT** The Xpert MTB/RIF assay (Xpert) is a rapid test for tuberculosis (TB) and rifampin resistance (RIF-R) suitable for point-of-care testing. However, it has decreased sensitivity in smear-negative sputum, and false identification of RIF-R occasionally occurs. We developed the Xpert MTB/RIF Ultra assay (Ultra) to improve performance. Ultra and Xpert limits of detection (LOD), dynamic ranges, and RIF-R *rpoB* mutation detection were tested on *Mycobacterium tuberculosis* DNA or sputum samples spiked with known numbers of *M. tuberculosis* H37Rv or *Mycobacterium bovis* BCG CFU. Frozen and prospectively collected clinical samples from patients suspected of having TB, with and without culture-confirmed TB, were also tested. For *M. tuberculosis* H37Rv, the LOD was 15.6 CFU/ml of sputum for Ultra versus 112.6 CFU/ml of sputum for Xpert, and for *M. bovis* BCG, it was 143.4 CFU/ml of sputum for Ultra versus 344 CFU/ml of sputum for Xpert. Ultra resulted in no false-positive RIF-R specimens, while Xpert resulted in two false-positive RIF-R specimens. All RIF-R-associated *M. tuberculosis* *rpoB* mutations tested were identified by Ultra. Testing on clinical sputum samples, Ultra versus Xpert, resulted in an overall sensitivity of 87.5% (95% confidence interval [CI], 82.1, 91.7) versus 81.0% (95% CI, 74.9, 86.2) and a sensitivity on sputum smear-negative samples of 78.9% (95% CI, 70.0, 86.1) versus 66.1% (95% CI, 56.4, 74.9). Both tests had a specificity of 98.7% (95% CI, 93.0, 100), and both had comparable accuracies for detection of RIF-R in these samples. Ultra should significantly improve TB detection, especially in patients with paucibacillary disease, and may provide more-reliable RIF-R detection.

**IMPORTANCE** The Xpert MTB/RIF assay (Xpert), the first point-of-care assay for tuberculosis (TB), was endorsed by the World Health Organization in December 2010. Since then, 23 million Xpert tests have been procured in 130 countries. Although Xpert showed high overall sensitivity and specificity with pulmonary samples, its sensitivity has been lower with smear-negative pulmonary samples and extrapulmonary samples. In addition, the prediction of rifampin resistance (RIF-R) in paucibacillary samples and for a few *rpoB* mutations has resulted in both false-positive and
false-negative results. The present study is the first demonstration of the design features and operational characteristics of an improved Xpert Ultra assay. This study also shows that the Ultra format overcomes many of the known shortcomings of Xpert. The new assay should significantly improve TB detection, especially in patients with paucibacillary disease, and provide more-reliable detection of RIF-R.

**KEYWORDS** Xpert MTB/RIF Ultra, diagnosis, sensitive, tuberculosis

**Tuberculosis** (TB) remains a global health threat despite the development of new diagnostics and antitubercular drugs. The Xpert MTB/RIF assay (Xpert) was developed to improve TB and rifampin resistance (RIF-R) detection. This was accomplished by automating most of the steps required to process clinical samples and by improving the sensitive detection of both *Mycobacterium tuberculosis* and RIF-R. Xpert uses a hemi-nested PCR to amplify the rifampin resistance-determining region (RRDR) of the *M. tuberculosis rpoB* gene (1). Five *rpoB* RRDR-specific molecular beacons are then used to detect both the presence of *M. tuberculosis* and mutations responsible for approximately 95% of RIF-R. In initial analytical studies, Xpert detected *M. tuberculosis* directly from sputum, with a limit of detection (LOD) of 131 CFU/ml (1). The assay can be performed in approximately 2 h. Pooled data have shown Xpert to have an overall sensitivity and specificity of approximately 89% and 98%, respectively (2). Due to its ease of operation and large-scale applicability in settings outside conventional laboratories, Xpert substantially improved the diagnosis of RIF-R and multidrug-resistant (MDR) TB (2–4). Between its endorsement by the World Health Organization (WHO) in 2010 and 2016, over 23 million Xpert tests have been procured in 130 countries, resulting in a 3- to 8-fold increase in testing for MDR TB worldwide (3).

Xpert has been noted to have a number of limitations. Despite its excellent sensitivity in tests of smear-positive sputum samples, Xpert is somewhat less sensitive when testing smear-negative sputum. For example, when Xpert was performed following negative smear microscopy results, its pooled sensitivity was 67% (2). Xpert was 43% sensitive in one study of HIV-positive patients with smear-negative TB (5), and its sensitivity was as low as 28% for smear-negative TB patients from a high-resource country with a low TB incidence (6). Clinical impact has also been lower than originally expected, perhaps due to Xpert’s suboptimal negative predictive value, although Xpert did lead to more correct TB treatment overall (7). Assay sensitivity has also been limited in some types of extrapulmonary samples, which are known to contain lower levels of bacilli than pulmonary samples (8–10). Xpert has generally performed very well as a rapid test for RIF-R, with a pooled sensitivity and specificity of 94% and 98%, respectively (2). However, the assay was noted to have a limited capacity to detect RIF-R-associated mutations in mixed samples (11, 12), and in some reports, it has a decreased capacity to detect *rpoB* C533G mutations responsible for some cases of RIF-R (13). Xpert may also generate occasional false-positive RIF-R calls for paucibacillary samples due to delays in the real-time signal generated by assay probes D and E (14). Its false recognition of a nonfunctional *rpoB* F514F silent mutation as conferring RIF-R has also been reported (15).

Seeking to resolve these limitations associated with Xpert, we developed a next-generation assay for TB and RIF-R detection that we have termed the Xpert MTB/RIF Ultra assay (Ultra). Here, we describe the changes in the design of the cartridge, thermal-cycling parameters, PCR, and mutation detection chemistry and the resulting improvements in both TB detection and identification of RIF-R.

**RESULTS**

**Sensitivity of Ultra versus that of Xpert.** The comparative analytical LODs of Ultra and Xpert were tested by spiking serial dilutions of quantified CFU into sputum samples (Fig. 1). *M. tuberculosis* strain H37Rv contains 16 copies of IS6110 and 5 copies of IS1081. For this test strain, Ultra and Xpert each detected the presence of both *M. tuberculosis* and RIF susceptibility correctly 100% of the time that a sample was tested, down to...
dilutions of 200 CFU/ml. At CFU inputs below 200, rates of correct TB-positive specimen detection by Xpert decreased to 85%, 50%, and 10% for 100, 50, and 25 CFU/ml, respectively. The calculated TB detection LOD for Xpert was 112.6 CFU/ml (95% confidence interval [CI], 91.9 to 158.2) (Fig. 1A). On the other hand, correct detection of TB-positive specimens by Ultra was 100% up to 25 CFU/ml. The calculated TB detection LOD for Ultra was 15.6 CFU/ml (95% CI, 12.2 to 23.1) (Fig. 1B), which represents an approximately 8-fold improvement over that of Xpert. The high sensitivity of Ultra was also evident at sub-LOD concentrations of added CFU, with 48% of the samples tested at 2.5 CFU/ml still positive by Ultra. Rates of detection of RIF susceptibility were comparable between Ultra and Xpert (LOD for RIF susceptibility by Xpert, 112.6 CFU/ml [95% CI, 91.9 to 158.2 CFU/ml] [Fig. 1C], versus LOD for RIF susceptibility by Ultra, 105.4 CFU/ml [95% CI, 78.5 to 178.8] [Fig. 1D]), although at sub-LOD concentrations, Ultra showed more positive results for RIF susceptibility than Xpert. Ultra also showed a substantial LOD improvement for detection of M. bovis BCG. In contrast to H37Rv, BCG contains only 1 copy of IS6110 and 5 copies of IS1081. Even under these circumstances, the BCG detection limit for Xpert was 344.1 CFU/ml (95% CI, 297.5 to 434.0) (see Fig. S1A in the supplemental material), compared to a BCG detection limit for Ultra of 143.4 CFU/ml (95% CI, 106.2 to 243.7) (Fig. S1B). As was the case with the H37Rv M. tuberculosis strain, with BCG, the LODs of RIF susceptibility detection were similar by the two assays, with a small improvement evident by Ultra (LOD for RIF susceptibility in BCG by Xpert, 338.8 CFU/ml [95% CI, 294.0 to 425.8]; LOD for RIF susceptibility in BCG by Ultra, 300.3 CFU/ml [95% CI, 244.2 to 408.2]) (Fig. S1C and D).

Detection of mutations associated with rifampin resistance and silent mutations. We had shown previously that a combination of three rpoB sloppy molecular

FIG 1  Limit of detection for M. tuberculosis H37Rv. The limit of detection of tuberculosis detection is shown for Xpert (A) versus Ultra (B). The limit of detection for generating a rifampin susceptibility rather than an indeterminate result is shown for Xpert (C) versus Ultra (D).
beacon (SMB) probes could be used in an assay to detect and differentiate *M. tuberculosis* RRDR mutations associated with RIF-R (16). For Ultra, we further refined a set of *rpoB* SMBs so that detection of RRDR codon 533 mutants associated with RIF-R was improved (particularly when the SMB probes were mixed with wild-type DNA). We also modified one of the *rpoB* SMBs so that it specifically differentiated the silent mutations Q513Q and F514F from other RRDR mutations that were associated with RIF-R. To improve detection of RRDR codon 533 mutants, we added an additional mutation-detecting *rpoB* SMB probe (rpo4), thereby expanding the *rpoB* SMB set from three to four. The rpo4 SMB was also designed to be more complementary to *rpoB* S531L mutants than to the wild-type sequence, which resulted in an increased melting temperature (Tm) in the presence of this mutation compared to the wild type’s Tm. To distinguish the silent mutations from RIF-R-associated mutations, we redesigned the rpo1 SMB probe so that its Tm increased upon hybridizing to Q513Q and F514F mutants compared to the Tm generated upon hybridizing to the wild-type sequence. This SMB probe continued to generate Tm values less than the wild type’s Tm when it hybridized to RRDR mutants associated with RIF-R. We challenged Ultra with 25 different RRDR mutations covering almost the entire *rpoB* RRDR from codons 510 to 533. The panel also included double and triple mutations, deletions, and stop codons and the Q513Q and F514F silent mutations (Table 1). The results showed that all mutations resulted in a reproducible and measurable shift in melting Tm peaks by one or more of the *rpoB* SMB probes (Fig. 2). Furthermore, each RIF-R-conferring mutation was reproducibly identified by the GeneXpert software as “RIF resistance detected,” except with a triple mutant that was identified as “RIF indeterminate” due to a Tm that was below the software’s mutation detection window (Table 1). In contrast, the two silent mutations Q513Q and F514F were identified as “RIF resistance not detected.” Xpert has been known to occasionally produce false RIF-R results in paucibacillary samples (14). However, we did not observe false RIF-R in this sample type using Ultra. Examining all Ultra runs performed on sputum spiked with ≤200 CFU/ml over a period of several months, 0/164 (0%) of the assays with a RIF susceptibility result were falsely resistant. In contrast, of all Xpert runs performed on sputum spiked with ≤200 CFU/ml over a similar period, 2/74 (2.7%) of the assays with a RIF susceptibility result were falsely positive.

### Table 1: Ultra mutation panel challenge

| Mutation(s) | Probe(s) for RIF-R detection | Ultra “test result” (semi-quantitation and RIF-R calls) |
|-------------|------------------------------|--------------------------------------------------------|
| None        | rpo1, rpo2                   | MTB DETECTED MEDIUM; RIF Resistance NOT DETECTED       |
| QS10V + D516Y | rpo1, rpo2                   | MTB DETECTED MEDIUM; RIF Resistance DETECTED          |
| LS11P       | rpo1                         | MTB DETECTED MEDIUM; RIF Resistance DETECTED          |
| S12T + MS15I + HS26N | rpo1, rpo2, rpo3 | MTB DETECTED MEDIUM; RIF Resistance DETECTED |
| QS13K       | rpo1                         | MTB DETECTED MEDIUM; RIF Resistance DETECTED          |
| QS13Q (silent) | rpo1                      | MTB DETECTED MEDIUM; RIF Resistance DETECTED          |
| FS14F (silent) | rpo1                      | MTB DETECTED MEDIUM; RIF Resistance DETECTED          |
| S16DEL      | rpo2                         | MTB DETECTED MEDIUM; RIF Resistance DETECTED          |
| DS16V       | rpo2                         | MTB DETECTED MEDIUM; RIF Resistance DETECTED          |
| S18DEL      | rpo2                         | MTB DETECTED MEDIUM; RIF Resistance DETECTED          |
| S522L       | rpo2, rpo3                   | MTB DETECTED MEDIUM; RIF Resistance DETECTED          |
| HS26C       | rpo3                         | MTB DETECTED MEDIUM; RIF Resistance DETECTED          |
| HS26D       | rpo3                         | MTB DETECTED MEDIUM; RIF Resistance DETECTED          |
| HS26L       | rpo3                         | MTB DETECTED MEDIUM; RIF Resistance DETECTED          |
| HS26N       | rpo3                         | MTB DETECTED MEDIUM; RIF Resistance DETECTED          |
| HS26R       | rpo3, rpo4                   | MTB DETECTED MEDIUM; RIF Resistance DETECTED          |
| HS26Y       | rpo3                         | MTB DETECTED MEDIUM; RIF Resistance DETECTED          |
| S26Stop     | rpo4                         | MTB DETECTED MEDIUM; RIF Resistance DETECTED          |
| RS29K       | rpo4                         | MTB DETECTED MEDIUM; RIF Resistance DETECTED          |
| S331L       | rpo4                         | MTB DETECTED MEDIUM; RIF Resistance DETECTED          |
| S331Q       | rpo4                         | MTB DETECTED MEDIUM; RIF Resistance DETECTED          |
| S331W       | rpo4                         | MTB DETECTED MEDIUM; RIF Resistance DETECTED          |
| LS33P       | rpo4                         | MTB DETECTED MEDIUM; RIF Resistance DETECTED          |
| LS33R       | rpo4                         | MTB DETECTED MEDIUM; RIF Resistance DETECTED          |
| LS33P + HS26S | rpo3, rpo4                | MTB DETECTED MEDIUM; RIF Resistance DETECTED          |
| LS30M + SS31P | rpo4                     | MTB DETECTED MEDIUM; RIF Resistance DETECTED          |
Detection of heteroresistance. We assessed the ability of Ultra to detect hetero-resistant DNA by testing mixtures of wild-type DNA and DNA containing the rpoB\textsuperscript{S531L} mutation, which is the most commonly occurring of the RRDR mutations (16). The rpo4 SMB probe was designed to generate a higher \(T_m\) value in the presence of the S531L mutation than that of the wild type. This probe design resulted in a predominating mutant peak in mixtures containing as little as 10\% mutant DNA and a distinct double peak in a proportion of mixtures containing as little as 5\% mutant DNA (Fig. 3), resulting in a GeneXpert output of “RIF resistance detected.” The assay failed intermittently to detect RIF-R in mixtures containing 5\% mutant samples and reproducibly failed to detect RIF-R in mixtures containing 0.5\% mutant DNA.

**FIG 2** Detection of \(M.\) \textit{tuberculosis} \(rpoB\) gene mutations associated with rifampin resistance. Derivative-transformed curves of four \(rpoB\)-specific sloppy molecular beacons (rpo1, rpo2, rpo3, and rpo4) first hybridized and then melted off of their \(M.\) \textit{tuberculosis} \(rpoB\) gene amplicon target are shown. Each colored peak indicates the melting temperature of the probe corresponding to the colored line. The peaks for wild-type \(M.\) \textit{tuberculosis} (A) identify a test sample as rifampin susceptible. The shift in one or more of the peaks away from the wild type’s melting temperature (B to G), identify a sample as an \(rpoB\) mutant and rifampin resistant. The shift in the melt peak is indicated by arrows.

**FIG 3** Detection of hetero-resistance. Samples containing equal quantities of total \(M.\) \textit{tuberculosis} DNA were created using different proportions of wild-type DNA and rifampin-resistant \(rpoB\) \textit{S533L} mutant DNA. Derivative-transformed curves of four \(rpoB\)-specific sloppy molecular beacons (rpo1, rpo2, rpo3, and rpo4) first hybridized and then melted off of their \(M.\) \textit{tuberculosis} \(rpoB\) gene amplicon target are shown. The presence of rifampin-resistant mutant DNA, as indicated by the peak marked with a red arrow, was consistently detected in samples containing as little as 10\% mutant DNA and in a subset of samples containing as little as 5\% mutant DNA. WT, wild type; mut., mutant.
this mutation only when the mutant DNA was present at \( \leq 1\% \) (Fig. 3). Heteroresistance detection for other RRDR mutations was not as sensitive as it was for the S531L mutation because these other mutations were detected by a downward \( T_{m} \) shift. However, even for the L511P and H526N RRDR mutations tested, RRDR mutations in mixtures containing \( rpoB \) mutant DNA at levels between 20% and 40% could still be reliably detected.

**Assay inclusivity.** We examined the capacity of Ultra to detect a wide variety of \( M. tuberculosis \) strains with varied numbers or no copies of IS6110. DNAs from 22 different clinical \( M. tuberculosis \) isolates and from one strain each of *Mycobacterium bovis*, *M. bovis* BCG, and *M. tuberculosis* H37Rv containing 0 to 18 copies of IS6110 (Table S1), representing 5 different genotypic lineages (17), were tested at a DNA input of approximately 4 times the estimated LOD of Ultra. The presence of *M. tuberculosis* was detected in all four replicates of each of the 25 different DNA samples (Table S1), indicating broad inclusivity.

**Analytical specificity and exclusivity.** The analytical specificity of the assay was tested on 30 different isolates of nontuberculous mycobacteria (NTM) and 18 different Gram-positive and -negative bacteria in triplicate samples to assess the cross-reactivity of the assay primers and probes. No signals were generated from the two *M. tuberculosis* detection probes targeting the IS6110 and IS1081 genes, with a result output of “MTB not detected” (where “MTB” stands for *M. tuberculosis*) for all the replicates tested. We observed weak rpo2 probe signals (average cycle threshold \([C_T]\) value of 30 or greater) for most of the NTM and additional rpo1 probe signals (average \( C_T \) of 36) for one replicate each of *Mycobacterium asiaticum*, *Mycobacterium interjectum*, and *Mycobacterium shimoidei*. However, these late signals from mostly a single rpoB probe did not lead to false *M. tuberculosis* or RIF-R detection, since none of these samples produced signals from the *M. tuberculosis*-specific probes and the assay does not proceed to melt analysis and RIF-R detection in the absence of an *M. tuberculosis*-specific signal. Additionally, we tested for the possibility that NTM might act as an interfering substance, which might confound TB detection in cases of mixed infection with both *M. tuberculosis* and an NTM. We mixed 10⁶ CFU/ml of the clinically relevant NTM, namely, *Mycobacterium abscessus*, *Mycobacterium avium*, *Mycobacterium intracellulare*, and *Mycobacterium kansasi* or the environmental contaminant *Mycobacterium gordonae*, with 50 CFU/ml of *M. tuberculosis*. Each of these mixtures was tested in triplicate. All tests showed the presence of RIF-susceptible TB, indicating that high background levels of NTM do not significantly interfere with the performance of Ultra for TB detection.

**Dynamic range and semiquantitative measurements compared to those of Xpert.** We performed repeated experiments with 10-fold serial dilutions of *M. tuberculosis* H37Rv and *M. bovis* BCG ranging from 10⁷ CFU/ml to 10 CFU/ml spiked in sputum to evaluate the dynamic range of Ultra. These results were compared to those generated by Xpert in tests of the same spiked samples (Fig. 4A). We used the lowest \( C_T \) generated among the four rpo probes during the nested-PCR stage of Ultra (or of the five rpoB probes of Xpert) as a semiquantitative measure of the *M. tuberculosis* cell number in each test sample. This semiquantitative measure is similar to that performed during routine clinical use of Xpert. In Ultra, sputum samples spiked with 10⁶ and 10⁵ CFU/ml of *M. tuberculosis* H37Rv generated similar average rpoB \( C_T \) values of approximately 19 to 20. Samples spiked with 10⁴ CFU/ml averaged only slightly higher rpoB \( C_T \) values of 20 to 21. From 10⁴ to 10 CFU/ml, average rpoB \( C_T \) values showed a linear relationship to CFU numbers (Fig. 4A). A similar trend was observed in sputum samples spiked with BCG, although the rpoB \( C_T \) values were slightly higher for each CFU. The relationship between the rpoB \( C_T \) value and input CFU also allowed us to classify samples into “high,” “medium,” “low,” and “very low” categories (Fig. S2). Most of the samples containing 100 CFU/ml were rpoB probe positive, resulting in “low” or “very low” result outputs. However, at CFU inputs below 100 CFU/ml, particularly in the range of 10 CFU/ml, the number of positive TB assays (i.e., IS6110/IS1081 positive) which also resulted in positive rpoB probe signals decreased to 20% or less, resulting in fewer *M. tuberculosis*-positive assays being associated with an rpoB \( C_T \) that could be used in
semiquantitative. We introduced the “trace” category to identify the paucibacillary samples which were IS11001/IS1081 positive but rpoB negative. Ultra tests of BCG dilutions behaved similarly, although the dynamic range curve appeared to flatten out at slightly higher numbers of CFU per milliliter for both H37Rv and BCG (Fig. 4A). In comparison, Xpert showed a better linear trend of the rpoB CT versus CFU input than did Ultra over the entire dynamic range, particularly at the higher concentrations of $10^7$ to $10^9$ CFU/ml, as shown for H37Rv in Fig. 4A. By definition, Xpert did not result in any tests that fell into the positive semiquantitative “trace” category. The altered relationship between the Ultra CT and the Xpert CT in samples with increasing numbers of CFU was even more apparent when Ultra and Xpert results were plotted against each other at each CFU dilution (Fig. 4B). For semi quantitative outputs, the following rpoB CT values were chosen for Ultra. CT values of 15 to 18.9 indicated “high,” 19 to 24.9 indicated “medium,” 25 to 28.9 indicated “low,” and 29 to 40 indicated “very low” levels of bacteria (Fig. S2). Together, these results show that the redesign of Ultra decreased the semiquantitative capacity at the high end of numbers of CFU per milliliter but retained this capacity in more paucibacillary samples corresponding to “/H11001,” “scanty,” and “smear negative.”

**Comparative performances of Ultra and Xpert on clinical sputum samples.** We performed a limited, retrospective evaluation of the performances of Ultra and Xpert using 277 sputum samples (Table 2). Compared to culture results, the overall sensitivity and specificity of Ultra for TB detection were 87.5% (95% CI, 82.1, 91.7) and 98.7% (95% CI, 93.0, 100%), respectively, and those of Xpert were 81.0% (95% CI, 74.9, 86.2) and 98.7% (95% CI, 93.0, 100%), respectively. The sensitivity of Ultra with the 109 smear negative-culture positive samples was 78.9% (95% CI, 70.0, 86.1) compared to 66.1% (95% CI, 56.4, 74.9) for Xpert, resulting in an approximately 13%-increased sensitivity for
Ultra. For smear-positive and culture-positive samples, the sensitivities of Ultra and Xpert were 97.8% (95% CI, 92.3, 99.7) and 98.9% (95% CI, 94.0, 100), respectively. RIF susceptibility results were available for 187/200 culture-positive samples. The sensitivity and specificity of Ultra for the detection of RIF susceptibility were 92.7% (95% CI, 80.1, 98.5) and 98.0% (95% CI, 92.8, 99.9), respectively, while that of Xpert were 92.7% (95% CI, 80.1, 98.5) and 99.0% (95% CI, 94.4, 100), respectively. One sample was detected as RIF resistant by Ultra; it was susceptible by both phenotypic susceptibility testing and Xpert. Upon Sanger sequencing, this sample was found to be hetero-resistant, with a mixture of the wild type and an rpoB S531L mutant. Reclassifying this sample as RIF resistant would change the sensitivity and specificity for RIF-R detection for Ultra to 92.9% (95% CI, 80.5, 98.3) and 99.0% (95% CI, 94.4, 100), respectively, and would change the sensitivity and specificity for RIF-R for Xpert to 90.3% (95% CI, 77.4, 97.3) and 99.0% (95% CI, 94.4, 100), respectively. Note that Ultra provided RIF resistance results for 20 samples that tested M. tuberculosis negative by Xpert and are excluded from the analysis of RIF resistance to provide accuracy estimates on the same sample set. Xpert was performed on a fresh sputum aliquot, and Ultra was tested retrospectively on a frozen aliquot of the same sputum sample.

**DISCUSSION**

We have developed an advanced version of the Xpert MTB/RIF assay with better TB detection capabilities and more definitive identification of RIF susceptibility and resistance. The (i) inclusion of two new PCR assays that target two different multicopy genes, (ii) conversion of the rpoB and IS6110 assays into fully nested PCRs, and (iii) use of a larger PCR tube that doubles the amount of sample DNA that can be tested have allowed for an almost 10-fold increase in analytical sensitivity for the detection of *M. tuberculosis* H37Rv. Importantly, this increase in sensitivity was not restricted only to H37Rv, which contains 16 copies of the IS6110 assay target. Sensitivity was also more than doubled for the detection of BCG, which contains only one IS6110 copy, suggesting that the additional sensitivity gained by Ultra is expected to be true for different clinical *M. tuberculosis* strains containing both high and low numbers of copies of IS6110. A limited study on frozen clinical samples which demonstrated improved sensitivity for Ultra compared to that of Xpert supports this conclusion. The inclusion of the IS1081 reaction also ensures that the assay will detect rare *M. tuberculosis* strains that do not contain any IS6110 genes (18), as shown by our analytical experiments that included a zero-copy-number IS6110 strain.

Ultra also enables improved detection of RRDR mutations associated with RIF-R. Both Xpert and Ultra detect RIF-R when one or more of the rpoB-specific molecular beacons used in the assays exhibit altered binding to an RRDR mutant DNA target. In Xpert, there is a C<sub>r</sub> delay in the binding of one of the molecular beacons to the mutant RRDR sequence relative to the binding of the remaining molecular beacons to the wild-type sequence. A delay (delta C<sub>r</sub>) of >4 cycles defines RIF-R. Unfortunately, this approach mistakenly identifies silent mutations as causes of RIF-R (15). Xpert also has a limited ability to identify hetero-resistance (11, 19), and small amounts of target DNA (as may occur in paucibacillary samples) can produce a C<sub>r</sub> delay which mimics a RIF-R hybridization pattern (14). We observed such false RIF-R calls from Xpert in our analytical experiments when low concentrations of *M. tuberculosis* and BCG CFU were tested; however, these falsely resistant calls were completely absent in the Ultra runs. The replacement of the delta C<sub>r</sub> approach for mutation detection with the delta T<sub>m</sub> approach (16) used in Ultra enabled us to resolve these limitations, producing a more
robust assay. An additional benefit of the delta \( T_m \) approach is that the many RRDR mutations can also be specifically identified by their \( T_m \) values (16).

The enhanced sensitivity of Ultra allowed us to identify more cases of smear-negative and culture-positive TB and more TB cases overall when Ultra was used on 277 sputum samples from TB suspects. Levels of RIF resistance detection were comparable between Xpert and Ultra, although Ultra detected a hetero-resistant sample that was missed by both phenotypic susceptibility testing and Xpert. Our analytic results have confirmed that Ultra has an improved ability to detect resistance in mixed samples, an observation that likely explains why Ultra detected RIF-R in the hetero-resistant clinical sample. Importantly, the manual steps required to perform Xpert and Ultra are identical. Furthermore, the two assays can be run in identical GeneXpert instruments after a software upgrade. Thus, it is expected that Ultra can be implemented with little additional training in sites that already use the current Xpert assay.

The increase in sensitivity provided by Ultra is not without certain risks. Increased sensitivity may predispose to false-positive results due to sample cross contamination, especially in laboratories that process numerous samples from TB suspects and \textit{M. tuberculosis} cultures. Furthermore, increased false-positive results have been noted when Xpert was used to test subjects with recent a history of TB (20). It is possible that Ultra will be even more predisposed to false-positive results in this situation. In this regard, our limited study on stored samples was performed at some sites with a relatively low population-level incidence of TB, and the specificity decrements for Ultra may be greater if the assay is implemented in high-TB-incidence countries. A prospective multicenter study will soon report on the clinical performance of Ultra compared to Xpert in a more representative TB population (21).

The Ultra assay analysis algorithm is designed to report a RIF-R result as indeterminate in most situations where \( \geq 1 \) of the \textit{rpoB} SMBs do not produce any measurable \( T_m \) peak. This was done to protect the assay from false-positive RIF-R calls in the rare (hypothetical) circumstance that a test performed below the LOD for RIF-R might produce \( \geq 1 \) but \( <4 \) \( T_m \) peaks. The consequence of this algorithm is that large RRDR deletions or multiple mutations might destabilize one or more of the \textit{rpoB} SMB probes sufficiently to eliminate any \( T_m \) in the temperature range measured by the assay. This might produce indeterminate RIF-R results in rare samples that are actually RRDR RIF-R mutants, as observed with a triple mutant in our analytical testing experiments (Table 1).

Our results suggest that Ultra will result in greater TB case detection rates not only in subjects with paucibacillary TB, such as those with HIV coinfection, but also in pediatric patients with TB and those with extrapulmonary TB, which are known to have lower mycobacterial loads. As TB elimination programs achieve initial successes, rates of paucibacillary TB should increase compared to rates of smear-positive disease. In this setting, assays with increased sensitivity, such as Ultra, may be instrumental in identifying the remaining cases of TB, and these assays are likely to prove valuable in furthering WHO goals to eradicate this disease.

**MATERIALS AND METHODS**

**Human-subject approvals.** This study was approved by the University of Medicine and Dentistry of New Jersey (now Rutgers University) Institutional Review Board (IRB; protocol numbers 02016000657 and 0120000104), by the ethics committee of the National Center for Tuberculosis and Lung Diseases of Georgia (protocol numbers IRB00007705 and IORG0006411), and by the ethics committee of P. D. Hinduja Hospital and Medical Research Center (IRB research protocol number 954-15-CR).

**Cartridge configuration and assay composition.** The Ultra assay cartridge is a modified version of the G4 cartridge used in Xpert (Cepheid, Sunnyvale, CA, USA). It consists of a multiposition fluidic valve, a bacterial-capture filter, and 11 chambers containing buffers needed for sample processing and PCR as described previously (1), and the integrated 25-\( \mu \)l capacity PCR tube was redesigned to have a 50-\( \mu \)l volume capacity. The primers and molecular beacon or TaqMan probes used in the assay were also changed relative to those of Xpert (see Tables S2 and S3 in the supplemental material). Ultra uses four relatively long sloppy molecular beacon (SMB) probes that together target the \textit{M. tuberculosis} RRDR to detect RIF-R, a function originally performed by five conventional molecular beacons targeted to the RRDR in Xpert (1). The alignment of the Xpert and Ultra probes targeting the \textit{rpoB} RRDR is shown in Fig. S3. Two additional probes, a TaqMan probe that targets the \textit{M. tuberculosis} multicopy \textit{IS6110} gene and a molecular beacon that targets the multicopy \textit{IS1081} gene, substitute for the \textit{rpoB} molecular
beacons used in Xpert to perform the task of *M. tuberculosis* detection. Each *rpoB*-specific SMB probe is labeled with a different fluorophore, allowing them to be individually analyzed. However, both the IS6110- and IS1081-specific probes are labeled with 6-carboxyfluorescein (FAM). As a consequence, a merged FAM signal generated by the combined signal of both FAM-labeled IS6110 and IS1081-specific probes is used to identify the presence of *M. tuberculosis*. The assay microfluidics of Ultra were modified from those of Xpert to add more volume of processed DNA to the PCR tube, and a faster PCR program was developed to enable an earlier time to result. The complete details of the cartridge configuration and reaction components are described fully in the supplemental material.

**Ultra procedure.** The sample treatment and cartridge loading processes used were the same as described previously for Xpert (1). Briefly, each sample (clinical sample, spiked sputum, or cultured *M. tuberculosis* CFU) was first mixed at a 2:1 ratio with a commercial NaOH- and isopropanol-containing sample reagent (SR; Cepheid, Sunnyvale, CA). The mixture was incubated for 15 min with occasional shaking and then added to the sample loading chamber of the cartridge for automatic processing as described fully in the supplemental material. The *M. tuberculosis* and RIF-R detection algorithm is shown in Fig. S4. The presence of *M. tuberculosis* was detected by the real-time signal from the probes targeting the multicopy IS6110 and IS1081 genes (22–24). The *Tm* values generated by the *rpoB* SMB probes were used to identify the presence of either the wild-type or the mutant RDRR DNA sequence. The cycle threshold (*Ct*) of the first positive *rpoB* probe was also used for Ultra’s semiquantitative function. The semiquantitative categories of high, medium, low, and very low were similar to those of Xpert. An additional semiquantitative category of “trace” was introduced in Ultra. The trace result identified samples that were *M. tuberculosis* positive due to the presence of the IS6110 and/or IS1081 molecular signals (*Ct* ≤ 37) in the absence of a signal from at least 3 of the *rpoB* SMBs. The “trace” category was designed to identify samples with the lowest number of *M. tuberculosis* targets. Automated TB detection and RIF sensitivity were determined by modified GeneXpert Diagnostics software (Cepheid, Sunnyvale, CA). Real-time PCR signals obtained during the second nested-amplification phase indicated the absence or presence of *M. tuberculosis*, which was followed by a post-PCR melting temperature (*Tm*) analysis only if the positive sample was not identified as “trace.” The *Tm* values generated from the *rpoB* SMB probes were then used to perform a RIF susceptibility call. The result outputs from the automated assay software were labeled as follows. (i) In the absence of any real-time signal other than the PCR internal control (IC), the result was “MTB not detected” (the assay did not proceed to melt). (ii) In the presence of the TB detection probe signal (*Ct* ≤ 37) and no more than one *rpoB* SMB-positive signal (*Ct* ≤ 40) along with the presence or absence of the IC signal, the result was “MTB trace detected but RIF resistance indeterminate” (the assay did not proceed to melt). (iii) In the presence of a TB signal plus ≥2 *rpoB* SMB signals, the assay was triggered to proceed to the post-PCR melt stage, and based on the *rpoB* probe *Ct*s and the *Tm* values obtained, the following calls were made: “MTB detected high/medium/low/very low” and “RIF resistance detected/not detected,” respectively (if <4 *rpoB* SMB probes generated *Tm* values under these circumstances, the output was changed to “RIF resistance indeterminate”). The distinct separation of the assay into the real-time amplification and post-PCR melt stages allowed the identification of TB-negative and “trace” TB samples within approximately 1 h and RIF susceptibility calls in less than 90 min. A full description of the assay parameters is provided in the supplemental material and Table S4.

**Analytical sensitivity testing of Ultra in comparison with Xpert.** The analytical sensitivity and limit of detection (LOD) of the extremely drug-resistant-TB assay was determined by spiking *M. bovis* BCG and an attenuated strain of *M. tuberculosis* H37Rv (mc6030) into *M. tuberculosis*-negative sputum and testing each sample according to a standard protocol as described in Text S1. Analytical sensitivity experiments were performed by spiking known numbers of CFU in sputum in a specific dilution series from 10^7 CFU/ml to 0 CFU/ml and performing the assay using a defined number of replicates (usually 20 per dilution). Xpert was performed on the same spiked sputum aliquots simultaneously with Ultra. The assay LOD was defined as the lowest number of CFU which, when spiked into 1 ml of sputum, would result in the detection of *M. tuberculosis* ≥95% of the time that a test was performed. The dynamic range of the assay was evaluated by performing similar experiments with spuata spiked with numbers of *M. tuberculosis* CFU ranging from 10^3 to 1/ml in multiple replicates, and the semiquantitative prediction capacities of Xpert and Ultra were then calculated and compared. A detailed description of CFU stock preparation and sputum spiking protocols are included in Text S1.

**Mutation panel challenge, hetero-resistance detection, and inclusivity testing.** The mutation panel challenge was performed using *M. tuberculosis* DNA provided by the Foundation of Innovative New Diagnostics (FIN Diagnostics) as well as DNA samples from clinical TB isolates maintained at Rutgers University. The DNA samples were isolated from a wide range of RIF-R clinical strains and confirmed by Sanger sequencing to contain a variety of mutations across the *rpoB* RRDR (Table 1). The Ultra cartridge was preloaded with the DNA of interest, the loaded cartridge placed into the GeneXpert instrument bay, and the assay performed by selecting a version of an automated assay protocol that was slightly modified to permit testing of DNA rather than CFU. The different wild-type and mutant DNA samples were run over a period of 6 months in 32 different modules in the GeneXpert instrument using different cartridge lots to check for *Tm* reproducibility. To test for the capacity of the assay to detect hetero-resistance, mutant DNA was added to wild-type DNA at various percentages, and the mixed DNA samples were run using the Ultra cartridges to evaluate the smallest amount of mutant DNA necessary in the mixed sample to trigger a RIF-R call. Inclusivity testing was performed on at least four replicates of DNA isolated from 25 different *M. tuberculosis* and *M. bovis* strains with various copies of IS6110, ranging from 0 copies to as many as 18 copies representing various genotypic lineages (Table S1). Appropriate positive (quantified *M. tuberculosis* DNA) and negative (PCR-grade water) controls were also run in multiple replicates with all the experiments.
Evaluation of analytical specificity and exclusivity. The analytical specificity and exclusivity of Ultra were performed using concentrated saturated bacterial liquid cultures (approximately 10⁷ to 10⁸ CFU/ml) of 30 different species of nontuberculous mycobacteria (NTM) and common bacterial microflora present in sputum and the upper respiratory tract. In the case of the Gram-positive and -negative bacteria for which culture was not available, 10⁶ genome equivalents of DNA were used instead of the culture. The NTM species included a laboratory strain of Mycobacterium smegmatis and several strains each of 29 different NTM isolates obtained from the ATCC repository (Manassas, VA) and National Jewish Health (Denver, CO), consisting of the following Mycobacterium species: M. abscessus, M. asiaticum, M. avium, M. celatum, M. chelonae, M. flavescens, M. fortuitum, M. gastri, M. genavense, M. gordoniae, M. goodii, M. hae-mophilum, M. interjectum, M. intracellulare, M. kansasi, M. marinum, M. malmoense, M. mucogenicum, M. per-egnum, M. phlei, M. scrofulaceum, M. shimoidaei, M. simiae, M. szulgai, M. terrae, M. thermofoissibile, M. triviale, M. xenopi, and M. vaccae. The Gram-positive and the Gram-negative bacteria included Staphylococcus agalactiae, Streptococcus pneumoniae, Streptococcus mitis, Streptococcus mutans, Streptococcus pyogenes, Staphylococcus aureus, Staphylococcus epidermidis, Haemophilus influenzae, Neisseria sp., Nocardia sp., Corynebacterium sp., Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii, Citrobacter freundii, Moraxella catarrhalis, and Enterobacter cloaceae. The Gram-positive and Gram-negative bacteria were not incubated in sample reagent for more than 2 min to prevent lysis prior to loading in the sample chamber. The NTM were incubated for the usual 15 min, as was done for M. tuberculosis. To check for the ability of Ultra to correctly detect M. tuberculosis against a background of NTM DNA, 10⁶ genome equivalents of NTM DNA were mixed with 50 genome equivalents of M. tuberculosis DNA and tested for TB detection and RIF-R calls. All the assays were performed using the Ultra cartridges as described above.

Retrospective accuracy study on clinical samples. The performance of Ultra on clinical sputum samples was done in a limited retrospective accuracy study at the National Reference Laboratories in Belarus and Georgia and at the P. D. Hinduja Hospital and Medical Research Center in Mumbai, India. The sputum samples used in the study consisted of two sets of well-characterized deidentified frozen samples from study participants presenting with symptoms compatible with TB. The first set (212 samples) came from the FIND specimen bank bio-repository, representing different geographical locations (Peru, Vietnam, South Africa), and the second set (65 samples) was prospectively collected at two of the sites (Georgia and India). Two sputum samples were characterized per study participant within 24 h of sputum collection, and testing included two sets of smear microscopy (either Ziehl-Neelsen or auramine O staining) and solid (Lowenstein Jensen media) and liquid (mycobacterial growth indicator tubes [MGIT]; Becton, Dickinson, Sparks, MD) cultures of each sample, followed by species confirmation for positive cultures (MPT64 antigen detection). RIF susceptibility was determined by either the proportion method on Lowenstein Jensen medium or the MGIT SIRE kit (Becton, Dickinson, Sparks, MD). Xpert was performed with 1 ml of fresh sputum sample, and Ultra was later performed on an approximately 1-ml frozen aliquot of the same sputum sample according to the manufacturer’s instructions (Cepheid, Inc., Sunnyvale, CA). The performances of Ultra and Xpert were evaluated against culture and RIF susceptibility testing as the gold standard.

Statistical analysis. For calculation of the LOD values, the percentages of the replicates resulting in successful TB detection and RIF susceptibility calls were calculated at each input CFU concentration in sputum for both Ultra and Xpert. Binary logistic regression results were fitted through the tested concentrations, and lower and upper 95% confidence intervals (95% CIs) were generated for the curve. The 95% CI for the minimum input concentration was determined by where the 95% probability level crossed the upper and lower 95% CIs, which indicated the LOD. Sensitivity and specificity values in the clinical accuracy study were calculated at the 95% CI for Ultra and Xpert.

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at https://doi.org/10.1128/mBio.00812-17.

TEXT S1, DOCX file, 0.03 MB.
FIG S1, EPS file, 2.4 MB.
FIG S2, EPS file, 1.2 MB.
FIG S3, EPS file, 1 MB.
FIG S4, EPS file, 1.3 MB.
TABLE S1, DOCX file, 0.01 MB.
TABLE S2, DOCX file, 0.02 MB.
TABLE S3, DOCX file, 0.02 MB.
TABLE S4, DOCX file, 0.01 MB.

ACKNOWLEDGMENTS

We thank Max Salfinger from National Jewish Health and Adrian M. Zelazny from the NIH Clinical Center for kindly providing us with the NTM strains used in this study.

D.A. receives income from licensees of Rutgers University’s molecular beacon patent pool, including a license to Cepheid for the use of molecular beacons in the Xpert MTB/RIF assay. To manage this conflict of interest, the income attributable to the
GeneXpert MTB/RIF assay which he may receive has been irrevocably capped at $5,000 per year. D.A. also reports receiving two research contracts from Cepheid. D.A. and S.C. report the filing of patents for primers and probes for detecting drug resistance in *M. tuberculosis*.

This work was funded by U.S. National Institutes of Health (NIH) grant AI111397 and a grant from the Foundation for Innovative New Diagnostics (FIND). Research support was also provided by Cepheid. Cepheid collaborated in analytical study design and performance, while FIND was involved in the clinical study planning, design, data collection, and analysis. The NIH had no role in study design, planning, or manuscript preparation.

REFERENCES

1. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, Kop J, Owens MR, Rodgers R, Banada P, Sañh H, Blakemore R, Lan NT, Jones-López EC, Levi M, Burday M, Ayakaka I, Mugenwa RD, McMillan B, Winn-Deen E, Christel L, Dailey P, Perkins MD, Persing DH, Alland D. 2010. Rapid detection of *Mycobacterium tuberculosis* and rifampin resistance by use of on-demand, near-patient technology. *J Clin Microbiol* 48:229–237. https://doi.org/10.1128/JCM.01463-09.

2. Steingart KR, Si HDJ, Pai M, Boehme CC, Dedukuri N. 2014. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 1:CD009593. https://doi.org/10.1002/14651858.CD009593.pub3.

3. Albert H, Nathavitharana RR, Isaacs C, Pai M, Denkinger CM, Boehme CC. 2016. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? *Eur Respir J* 48:516–525. https://doi.org/10.1183/13993003.00453-2016.

4. Boehme CC, Nabeta P, Hillmanen D, Nicola MP, Shenai S, Krapf F, Allen J, Tahiril R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD. 2010. Rapid molecular detection of tuberculosis and rifampin resistance. *N Engl J Med* 363:1005–1015. https://doi.org/10.1056/NEJMoa097847.

5. Lawn SD, BrooksSV, Kranzer K, Nicola MP, Whitelaw A, Vogt M, Bekker LG, Wood R. 2011. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. *PLoS Med* 8:e1001067. https://doi.org/10.1371/journal.pmed.1001067.

6. John H, Aevo AD, Menzies D, Behr M, Schwartzman K, Alvarez GG, Dan A, McIntosh F, Pai M, Denkinger CM. 2014. Xpert MTB/RIF testing in a low tuberculosis incidence, high-resource setting: limitations in accuracy and clinical impact. *Clin Infect Dis* 58:970–976. https://doi.org/10.1093/cid/ciu202.

7. Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, Bara W, Munogo S, Pai M, Hoelscher M, Dowdy D, Pym A, Mason P, Peter J, Dheda K, TB-NEAT Team. 2014. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. *Lancet* 383:424–435. https://doi.org/10.1016/S0140-6736(13)62073-5.

8. Theron G, Peter J, Calligaro G, Meldau R, Hanrahan C, Khalfey H, Matinyena B, Muchinga T, Smith L, Pandie S, Patel V, Mayosi BM, Dheda K. 2014. Determinants of PCR performance (Xpert MTB/RIF), including bacterial load and inhibition, for TB diagnosis using specimens from different body compartments. *Sci Rep* 4:5658. https://doi.org/10.1038/srep05658.

9. Zeka AN, Tshaban K, Cavusoglu C. 2011. Evaluation of the GeneXpert MTB/RIF assay for rapid diagnosis of tuberculosis and detection of rifampin resistance in pulmonary and extrapulmonary specimens. *J Clin Microbiol* 49:4136–4141. https://doi.org/10.1128/JCM.05434-11.

10. Denkinger CM, Schumacher SG, Boehme CC, Dedukuri N, Pai M, Steingart KR. 2014. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. *Eur Respir J* 44:435–446. https://doi.org/10.1183/09031936.0007814.

11. Blakemore R, Story E, Helb D, Kop J, Banada P, Owens MR, Chakravorty S, Jones M, Alland D. 2010. Evaluation of the analytical performance of the Xpert MTB/RIF assay. *J Clin Microbiol* 48:2495–2501. https://doi.org/10.1128/JCM.00128-10.

12. Zetola NM, Shin SS, Temuda KA, Moeti K, Ncube R, Nicola M, Collinan RG, Klausner JD, Modongo C. 2014. Mixed Mycobacterium tuberculosis complex infections and false-negative results for rifampicin resistance by GeneXpert MTB/RIF are associated with poor clinical outcomes. *J Clin Microbiol* 52:2422–2429. https://doi.org/10.1128/JCM.02489-13.

13. Rufai SB, Kumar P, Singh A, Prajapati S, Balooni V, Singh S. 2014. Comparison of Xpert MTB/RIF with line probe assay for detection of rifampin-monoresistant Mycobacterium tuberculosis. *J Clin Microbiol* 52:1846–1852. https://doi.org/10.1128/JCM.03005-13.

14. Williamson DA, Basu L, Bowler J, Forrest J, Henderson G, Roberts SA. 2012. An evaluation of the Xpert MTB/RIF assay and detection of false-positive rifampicin resistance in *Mycobacterium tuberculosis*. *Diagn Microbiol Infect Dis* 74:207–209. https://doi.org/10.1016/j.diagmicrobio.2012.06.013.

15. Köser CU, Feuereigol S, Summers DK, Archer JA, Niemann S. 2012. Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance. *Antimicrob Agents Chemother* 56:6080–6087. https://doi.org/10.1128/AAC.01641-12.

16. Chakravorty S, Kothari H, Alagedambi B, Cho EJ, Lee JS, Roh SS, Kim H, Kwak H, Lee EG, Hwang SH, Banada PP, Safi H, Via LE, Cho SN, Barry CE III, Alland D. 2012. Rapid, high-throughput detection of rifampin resistance and heteroresistance in Mycobacterium tuberculosis by use of sloppy molecular beacon melting temperature coding. *J Clin Microbiol* 50:2194–2202. https://doi.org/10.1128/JCM.00143-12.

17. Gagneux S, Small PM. 2007. Global phylogeny of *Mycobacterium tuberculosis* and implications for tuberculosis product development. *Lancet Infect Dis* 7:328–337. https://doi.org/10.1016/S1473-3099(07)70108-1.

18. Lok KH, Benjamini WH, Jr, Kimerling ME, Pruittt V, Lathan M, Razeeq J, Hooper N, Cronin W, Dunlap NE. 2002. Molecular differentiation of *Mycobacterium tuberculosis* strains without IS6110 insertions. *Emerg Infect Dis* 8:1310–1313. https://doi.org/10.3201/eid0811.020291.

19. Ioannidis P, Papaventis D, Karabela S, Nikolau S, Fanagi M, Raftopoulous K, Konstantinidou E, Marinou J, Kanavaki S. 2011. *Cepheid GeneXpert MTB/RIF* assay for *Mycobacterium tuberculosis* detection and rifampicin resistance identification in patients with substantial clinical indications of tuberculosis and smear-negative microscopy results. *J Clin Microbiol* 49:3068–3070. https://doi.org/10.1128/JCM.00718-11.

20. Boyles TH, Hughes J, Cox V, Burton R, Meintjes G, Mendelson M. 2014. False-positive Xpert® MTB/RIF assays in previously treated patients: need for caution in interpreting results. *Int J Tuberc Lung Dis* 18:876–878. https://doi.org/10.5888/ijtld.13.0853.

21. Schumacher SG, Nabeta P, Boehme CC, Ellner J, Alland D, Dommane S, Denkinger CM. 2017. A multicenter diagnostic accuracy study of the Xpert Ultra for tuberculosis diagnosis. *Conf Retroviruses Opport Infect, Seattle, WA, 13 to 16 February 2017. http://www.croiconference.org/sessions/multicenter-diagnostic-accuracy-study-xpert-ultra-tuberculosis-diagnosis/.

22. Eisenach KD, Crawford JT, Bates JH. 1988. Repetitive DNA sequences as probes for Mycobacterium tuberculosis. *J Clin Microbiol* 26:2240–2245.

23. Thierry D, Cave MD, Eisenach KD, Crawford JT, Bates JH, Gicquel B, Guesdon JL. 1990. IS6110, an IS-like element of *Mycobacterium tuberculosis* complex. *Nucl Soc* 18:188. https://doi.org/10.1093/nar/18.8.

24. van Soolingen D, Hermans PW, de Haas PE, van Embden JD. 1992. Insertion element IS1081-associated restriction fragment length polymorphisms in *Mycobacterium tuberculosis* complex species: a reliable tool for recognizing *Mycobacterium bovis* BCG. *J Clin Microbiol* 30:1772–1777.